Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002588 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00002588 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00002588, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of topotecan and etoposide in treating patients who have recurrent or refractory leukemia.
Interventions
- DRUG etoposide
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1994-08 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002588
The ClinicalTrials.gov registry entry for NCT00002588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.
NCT00002588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002588 about?
NCT00002588 is a clinical study titled "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of topotecan and etoposide in treating patients who have recurrent or r...
What is the current status of trial NCT00002588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1994-08. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00002588?
The interventions under investigation include: etoposide (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002588?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.